After a grueling battle to fight off unwanted acquirer Horizon Pharma last year, Depomed finds itself in another precarious position. The pain drug maker is now facing a battle with an activist investor that says it's shirking its fiduciary duties.
Starboard Value LP, which holds 6.8% of the company as of April 8, said in a filing with the US...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
